POC diagnostics are shifting from labs to bedside, compressing performance demands across devices and consumables. EU IVDR is raising the clinical and analytical evidence bar, including for products already on market.
The critical gap is not scientific, it is between lab-proven assay performance and manufacturing reproducibility at scale. Dossiers lacking production-stage data remain the leading cause of submission delays.
The industry is consolidating around partners where design, assay, and manufacturing operate under one program logic. Compliance must be engineered from Day 1. Analytical validation only holds regulatory weight when grounded in real production conditions.
Serving these domains demands more than technical range, it demands assay-aligned manufacturing depth.
Initial ideas are translated into viable product concepts through user needs analysis, market insights, and technical feasibility studies. Early risk assessment and proof-of-concept validation help confirm practicality and define the overall development direction.
High-sensitivity detection spanning clinical chemistry and rapid-test formats, across FIA, CLIA/ECLIA, ELISA, and fluorescence/chemiluminescence immunoassay architectures.
Whether you are developing a next-generation molecular diagnostic system, a point-of-care device, or high-volume consumables, we help you transform validated science into compliant, scalable commercial success.
Whether you are developing a next-generation molecular diagnostic system, a point-of-care device, or high-volume consumables, we help you transform validated science into compliant, scalable commercial success.
AI-Powered Assistant
